Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
- 20 October 2022
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (1) , 56-65
Abstract
Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective analysis to determine prognostic variables associated with development of RT and overall survival (OS) at progression after treatment with ibrutinib. We identified 559 patients with CLL treated with ibrutinib from 2010–2019. After a median follow‐up of 44.5 months from ibrutinib start, 179 patients progressed and were included in our analysis. After a median follow‐up of 20.8 months from progression, 54 out of 179 patients developed RT. Progression on treatment (hazard ratio [HR] 4.01 [1.60–10.00], p = .003), higher LDH (HR 1.80 for 2‐fold increase [1.33–2.43], p = .0001), and lymphadenopathy without lymphocytosis (HR 2.88 [1.15–7.20], p = .02) were independent prognostic variables for the development of RT at progression. Progression with lymphadenopathy without lymphocytosis continued to be an independent prognostic variable of worse OS post‐progression. In a subset analysis of 50 patients who obtained a PET‐CT at progression, the median SUVmax for patients who would develop RT was 15.2 (n = 30, range: 4.0–46.3) versus those patients who did not develop RT with a SUVmax of 7.7 (n = 20, range: 2.3–27.2) (p = .0030). Median OS from date of RT was 4.0 months, suggesting that prognosis for RT remains poor. A lymph node biopsy to rule out RT should be considered in patients who received ibrutinib who progress on treatment, have an elevated LDH, or progress with lymphadenopathy without lymphocytosis.Keywords
This publication has 24 references indexed in Scilit:
- Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLLLeukemia, 2016
- An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s SyndromeLeukemia & Lymphoma, 2015
- Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2015
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2015
- Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive diseaseLeukemia, 2015
- Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemiaBlood, 2014
- Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patientsBritish Journal of Haematology, 2013
- Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndromeBritish Journal of Haematology, 2008
- Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell TransplantationJournal of Clinical Oncology, 2006
- Richter's syndrome: a report on 39 patients.Journal of Clinical Oncology, 1993